FDA Sets Class II Rules for Ingestible Constipation Devices

Most manufacturers read a device classification order the wrong way. They see the name of the one company that went through De Novo review, file it under "not relevant to us," and move on. That's the mistake. When FDA takes a genuinely new device through the De Novo pathway and later locks the outcome into the Code of Federal Regulations, it isn't just blessing one product. It's publishing a template: the special controls, the testing expectations, the labeling standard that anyone building something reasonably similar can now point to instead of starting from zero.

That's what happened on June 1, 2026, when FDA finalized 21 CFR 876.5940, formally classifying the "orally ingested transient device for constipation" into class II with special controls. If your pipeline includes an ingestible device, a GI device, or anything that leans on a similarly novel mechanism of action, the lesson isn't "here's a new device on the market." It's "here's a faster, cheaper route to market for anything close enough to it."

What Actually Changed on June 1, 2026

FDA published the final order in the Federal Register (91 FR 32347, Docket No. FDA-2026-N-5196), creating a new regulation, 21 CFR 876.5940, inside Part 876 (Gastroenterology-Urology Devices). The order defines the device type as an electric swallowable capsule that naturally passes through the gastrointestinal tract for the treatment of constipation, and it assigns that device type to class II subject to special controls rather than class III subject to premarket approval.

Here's the detail that matters more than the device description: this classification order didn't create the special controls out of nothing. FDA granted the underlying De Novo request, submitted by Vibrant Ltd. on November 30, 2021, back on August 26, 2022. The June 2026 Federal Register notice is FDA formally codifying a decision it already made almost four years earlier. That gap between grant and codification is itself worth sitting with for a second, because it tells you something about how FDA actually operates versus how the regulations describe it operating on paper.

More than three and a half years passed between the day FDA granted the original De Novo request for this device type and the day the classification regulation took legal effect in the CFR. That's not a delay caused by anything Vibrant Ltd. did wrong. It's simply how long it takes FDA to move a novel classification from "granted to one company" to "codified for the whole market." If you're planning your own De Novo strategy around when a product category becomes generally available to competitors, plan around years, not months.

Why This Is a Market Signal, Not Just a Product Update

A class III De Novo grant benefits exactly one company: the requester. A codified class II classification benefits everyone. Once a device type sits in the CFR with defined special controls, subsequent manufacturers of substantially equivalent devices can submit a 510(k) referencing that classification instead of filing their own De Novo request. That's the entire point of the De Novo pathway under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act: it exists to let FDA and a would-be first-mover establish a new regulatory category so that everyone who comes after doesn't have to.

The company that files first absorbs years of regulatory uncertainty and cost. The companies that follow inherit a paved road. In my experience advising device manufacturers, this is exactly where the second-mover advantage lives: you get the benefit of a known special-controls checklist without needing to win an argument with FDA about whether your device category should even exist.

The Seven Special Controls Behind 21 CFR 876.5940

FDA's final order lists the special controls that now apply to any orally ingested transient device for constipation. If you're building a competing or follow-on device, this list is your design verification and validation roadmap, not a suggestion:

1. Clinical performance data. You need clinical evidence demonstrating both device performance and patient safety for the intended constipation indication, not just bench data.
2. Non-clinical performance testing. Dimensional testing, functional testing, leak testing, bite resistance, and pH resistance across the range of GI conditions the device will transit.
3. Biocompatibility evaluation. Every patient-contacting component needs biocompatibility data appropriate to an ingested device with mucosal and GI-tissue contact.
4. Shelf life validation. Package integrity testing and functional testing across the labeled shelf life, since an ingestible electronic device has to still work correctly after months in packaging.
5. Software verification, validation, and hazard analysis. Because this is an electric capsule, not an inert one, software V&V and hazard analysis apply the same way they would to any electromechanical device.
6. Electrical safety and EMC testing. Electromagnetic compatibility testing to confirm the device doesn't malfunction from, and doesn't cause, electromagnetic interference.
7. Labeling requirements. Labeling must include a clinical summary and shelf-life information, not just standard instructions for use.

Seven distinct control categories is a lot for what sounds, on the surface, like a simple pill. That's the point. FDA is comfortable with class II here precisely because the special controls are specific enough to substitute for the general safety review a PMA would otherwise require.

The Risks FDA Is Actually Managing

Every special control traces back to a risk FDA identified during its De Novo review. Understanding the pairing helps you write a 510(k) that FDA will actually accept rather than one that technically checks every box while missing the underlying concern.

Notice that almost every risk maps to more than one control. FDA rarely relies on a single test method to manage a single risk in a special controls order. If your design history file addresses each risk with only one line of evidence, expect an additional information request.

What This Means If You're Building a Competing Device

If you're developing an ingestible device anywhere near this category, three things follow from the June 2026 order:

First, you likely no longer need a De Novo request. If your device is substantially equivalent to the classified device type, a 510(k) citing 21 CFR 876.5940 as the predicate classification is now the intended pathway. That alone can shave a year or more off your regulatory timeline compared to what Vibrant Ltd. went through.

Second, your design controls need to produce all seven special-control data sets before you submit, not after. FDA doesn't accept a 510(k) with a promise to complete biocompatibility testing post-clearance for this device type. The special controls are premarket requirements.

Third, check the product classification database before you assume you're covered. FDA assigns a specific product code to this device type in its device classification database. Confirm your device's intended use and technological characteristics actually match the codified definition — an electric swallowable capsule that naturally passes through the GI tract for constipation treatment — before you build a submission strategy around this predicate. A device that shares a market category but not the mechanism of action may still need its own De Novo.

Why This Also Matters Under the New QMSR

There's a second regulatory shift compounding this one, and I'd be doing you a disservice if I didn't connect the two. As of February 2, 2026, FDA's Quality Management System Regulation replaced the old 21 CFR Part 820 quality system regulation by incorporating ISO 13485:2016 by reference. Every one of the seven special controls above, clinical data, non-clinical testing, biocompatibility, shelf life, software V&V, electrical safety, and labeling, has to be generated and documented inside a quality system that now maps directly to ISO 13485:2016 clause 7.3 design and development controls, not the legacy 820.30 language.

For manufacturers preparing a 510(k) under this new classification, that means your design history file, your risk management file under ISO 14971, and your software lifecycle documentation all need to satisfy ISO 13485:2016 structure, not just FDA's special controls checklist layered on top of an old QSR framework. If your quality system transition to the QMSR isn't finished, a special-controls-heavy submission like this one is exactly the kind of project where the gap shows up first. Our guide to the QMSR transition and ISO 13485 alignment walks through what has to change in your documented procedures.

Effective Dates and Deadlines at a Glance

There's no public comment period attached to this specific action. Classification final orders issued under section 513(f)(2) codify a De Novo decision FDA already made, so they take effect on publication rather than going through notice-and-comment rulemaking. If you disagree with how FDA classified the device type, your remedy is a reclassification petition under 21 CFR 860.123, not a comment on this docket.

Practical Compliance Steps

If this classification touches your product roadmap, here's the order I'd work through it:

1. Confirm predicate fit. Compare your device's mechanism of action against the codified definition in 21 CFR 876.5940 before assuming a 510(k) pathway is available to you.
2. Build your special controls matrix early. Map each of the seven special controls to a specific test protocol and a specific person or lab responsible for it, before you lock your design.
3. Verify your quality system is QMSR-ready. Confirm your design and development procedures reference ISO 13485:2016 clause 7.3, not the retired 21 CFR 820.30 language, since FDA reviewers will expect QMSR-aligned documentation for anything submitted after February 2, 2026.
4. Pressure-test your clinical data package. Two separate special controls (clinical performance data and labeling with a clinical summary) both depend on the same underlying study. Weak clinical data doesn't just fail one control, it fails two.
5. Check the product code assignment. Confirm with FDA's classification database, or with regulatory counsel, that your specific device configuration falls under this product code before you finalize your 510(k) strategy.

Why Constipation Devices, Specifically, Right Now

Chronic constipation is not a niche condition. Researchers commonly estimate that chronic constipation affects somewhere around 16 percent of adults in the United States at any given time, which is a large enough population that a lower-barrier device pathway has real commercial weight behind it. That prevalence is exactly why FDA's decision to codify a class II pathway here, rather than leave every new entrant to fight through De Novo individually, matters beyond one company's product line. The substantial majority of new device submissions FDA receives in any given year arrive through the 510(k) pathway rather than De Novo or PMA, which is the whole reason a codified classification is worth more to the market than a single De Novo grant sitting in FDA's database unreferenced.

FAQ

What device triggered this classification, and is it already on the market? The classification stems from a De Novo request by Vibrant Ltd., granted by FDA on August 26, 2022, for an electric swallowable capsule that treats constipation by naturally passing through the GI tract. The June 1, 2026 order formally codifies that device type into 21 CFR 876.5940 for the whole market, not just the original requester.

What's the difference between a De Novo grant and this classification order? A De Novo grant applies to one company's specific device. A classification final order takes that decision and writes it into the CFR as a device type, which opens a 510(k) pathway for any subsequent manufacturer with a substantially equivalent device, rather than requiring each new entrant to file its own De Novo request.

Does this classification create a comment period or a compliance deadline I need to track? No. Classification final orders issued under section 513(f)(2) codify a decision FDA already made through the De Novo process, so they take effect on publication, June 1, 2026 here, without prior notice-and-comment. If you want to challenge the classification itself, the mechanism is a reclassification petition under 21 CFR 860.123.

What are the special controls I need to satisfy for a 510(k) under 21 CFR 876.5940? Seven categories: clinical performance data, non-clinical performance testing (dimensional, functional, leak, bite, and pH resistance), biocompatibility evaluation, shelf life validation, software verification and validation with hazard analysis, electrical safety and EMC testing, and labeling that includes a clinical summary and shelf-life information.

Does the new QMSR change how I document compliance with these special controls? Yes. Since February 2, 2026, FDA's Quality Management System Regulation incorporates ISO 13485:2016 by reference in place of the legacy 21 CFR Part 820 quality system regulation. Your design history file and risk management documentation for a device under this classification need to reflect ISO 13485:2016 clause structure, particularly clause 7.3 design and development controls, not the retired 820.30 framework.

Last updated: 2026-08-05